Cooley represented Turnstone, and Latham & Watkins represented the underwriters in the IPO. Turnstone Biologics Corp. (Nasdaq: TSBX) announced the pricing of its upsized initial public...
You must be a Standard 1 Year member to access this content.
Cooley advised SCYNEXIS on the deal. SCYNEXIS announced its exclusive license agreement with GSK for Brexafemme. The exclusive license agreement gives GSK rights to commercialize SCYNEXIS’ ibrexafungerp...
You must be a Standard 1 Year member to access this content.
Cooley LLP and Matheson LLP advised Horizon, while Sullivan & Cromwell LLP and William Fry LLP advised Amgen. Debevoise & Plimpton LLP advised JP Morgan. Macfarlanes...
You must be a Standard 1 Year member to access this content.
Cooley advised Neogene Therapeutics on the deal. Neogene Therapeutics, a global clinical-stage biotechnology company, signed its definitive agreement to be acquired by AstraZeneca for a total consideration...
You must be a Standard 1 Year member to access this content.
Davis Polk advised European Biotech Acquisition Corp. on the deal while Cooley and Vischer represented Oculis. European Biotech Acquisition Corp. (EBAC), a SPAC, signed its $200 million...
You must be a Standard 1 Year member to access this content.
Goodwin Procter and Debevoise & Plimpton advised Carlyle on the deal, while Cooley and Gilbert+Tobin advised Opthea. Global investment firm Carlyle and its life sciences franchise...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Blueprint Medicines Corporation on the deal while Cooley represented Sixth Street. Blueprint Medicines Corporation (NASDAQ: BPMC) announced its strategic financing collaborations with Sixth...
You must be a Standard 1 Year member to access this content.
